Purpose: Adenosine deaminase (ADA) deficiency is a systemic disorder of purine metabolism. Deficiency of the purine salvage enzyme ADA leads to the build-up of the toxic metabolites, deoxyadenosine triphosphate and deoxyadenosine. ADA is ubiquitously expressed in all tissues of the body but most profoundly affects lymphocyte development and function leading to severe combined immunodeficiency (SCID). Unlike most other forms of SCID, ADA deficiency also results in non-immunologic manifestations. Associations between ADA deficiency and sensorineural hearing loss, behavioural abnormalities, non-infectious pulmonary disease and skeletal dysplasia are all recognised, and affect the long term outcome for these patients. Identification of new non-immunological manifestations and clinical presentations of ADA deficiency is essential to allow early optimisation of supportive care.

Methods And Results: Here we report four patients with ADA deficiency whose presenting feature was haemolytic uremic syndrome (HUS). 3 of 4 patients were diagnosed with ADA deficiency only after developing HUS, and one diagnosis was made post mortem, after a sibling was diagnosed with SCID. Shiga-toxigenic organisms were not isolated from any of the patients. 2 patients made a good recovery from their HUS with supportive treatment and initiation of PEG-ADA. Both remain well on enzyme replacement with mild or no residual renal impairment.

Conclusions: Clinicians should be aware of this previously unreported non-immunologic manifestation of ADA deficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-015-0158-0DOI Listing

Publication Analysis

Top Keywords

ada deficiency
28
ada
9
adenosine deaminase
8
severe combined
8
combined immunodeficiency
8
deficiency
8
patients
5
deaminase deficient
4
deficient severe
4
immunodeficiency presenting
4

Similar Publications

Urticarial vasculitis.

Curr Opin Rheumatol

January 2025

Marmara University School of Medicine, Department of Dermatology, Istanbul, Türkiye.

Article Synopsis
  • Urticarial vasculitis (UV) is a rare condition that can range from mild skin issues to serious systemic problems, and recent research focuses on its causes, diagnosis, and treatment options.
  • New triggers for UV associated with SARS-CoV-2 and COVID-19 vaccines have been noted, along with a new clinical-dermoscopic method for diagnosis that reduces reliance on skin biopsies.
  • Treatments such as antihistamines, corticosteroids, and rituximab show promise for success and long-lasting remission, while epidemiological studies show good survival rates but highlight certain severe health issues that can increase mortality.
View Article and Find Full Text PDF

Prolonged diagnostic journey in delayed-onset adenosine deaminase deficiency.

Clin Immunol

January 2025

Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Electronic address:

Adenosine deaminase (ADA) deficiency typically presents as a severe combined immunodeficiency in early infancy, although its onset may be delayed in some cases. We encountered two patients diagnosed with ADA deficiency in adulthood. In addition to previously reported cases, we aimed to identify and characterize the clinical and immunological features associated with delayed- and late-onset ADA deficiency.

View Article and Find Full Text PDF

Successful Long-Term Enzyme Replacement Therapy in a Patient with Delayed-Onset ADA Deficiency.

J Clin Immunol

September 2024

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.

View Article and Find Full Text PDF

Background: Deficiency of adenosine deaminase (ADA or ADA1) has broad clinical and genetic heterogeneity. Screening techniques can identify asymptomatic infants whose phenotype and prognosis are indeterminate, and who may carry ADA variants of unknown significance.

Objective: We systematically assessed the pathogenic potential of rare ADA missense variants to better define the relationship of genotype to red blood cell (RBC) total deoxyadenosine nucleotide (dAXP) content and to phenotype.

View Article and Find Full Text PDF

Deficiency of Adenosine Deaminase 2.

Turk J Haematol

August 2024

Hacettepe University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Türkiye

Article Synopsis
  • Adenosine deaminase 2 deficiency is an inherited autoinflammatory disorder caused by mutations leading to an inflammatory response, characterized by high levels of inflammatory cytokines and issues with neutrophil function.
  • The condition presents a wide range of symptoms beyond vasculitis, including hematological and immunological issues, requiring diagnosis through genetic testing and measurement of enzyme activity.
  • Current treatments focus on TNF-α inhibitors for controlling vasculitis, while severe cases may benefit from stem cell transplants; future therapies may include recombinant protein and gene therapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!